GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Hisun Pharmaceutical Co Ltd (SHSE:600267) » Definitions » Scaled Net Operating Assets

Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Scaled Net Operating Assets : 0.69 (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zhejiang Hisun Pharmaceutical Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Zhejiang Hisun Pharmaceutical Co's operating assets for the quarter that ended in Sep. 2024 was ¥14,773 Mil. Zhejiang Hisun Pharmaceutical Co's operating liabilities for the quarter that ended in Sep. 2024 was ¥3,076 Mil. Zhejiang Hisun Pharmaceutical Co's Total Assets for the quarter that ended in Jun. 2024 was ¥16,926 Mil. Therefore, Zhejiang Hisun Pharmaceutical Co's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.69.


Zhejiang Hisun Pharmaceutical Co Scaled Net Operating Assets Historical Data

The historical data trend for Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Hisun Pharmaceutical Co Scaled Net Operating Assets Chart

Zhejiang Hisun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.67 0.65 0.67 0.66

Zhejiang Hisun Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.69 0.69 0.68 0.69

Competitive Comparison of Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets falls into.


;
;

Zhejiang Hisun Pharmaceutical Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(16026.362-3571.839)/18777.991
=0.66

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=17613.282 - 1586.92
=16026.362

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=9263.868 - 2397.58 - 3294.449
=3571.839

Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(14773.011-3076.129)/16925.539
=0.69

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=16256.996 - 1483.985
=14773.011

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=7761.441 - 1325.131 - 3360.181
=3076.129

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Hisun Pharmaceutical Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Zhejiang Hisun Pharmaceutical Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Hisun Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 46 Waisha Road, Jiaojiang District, Zhejiang Province, Taizhou, CHN, 318000
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
Executives
Yu Shun Bing Supervisors
Jin Hong Shun senior management
Lu Xing Hai senior management
Zhang Zhen Ying senior management
Jiang Guo Ping Director
Yang Zhi Qing senior management
Du Jia Qiu senior management
Chen Xiao Hua Directors, senior managers
Li Yan Directors, senior managers
Zhao Lei senior management
Shen Xi Fei Director
Zhang Wei senior management
Bai Hua Director
Chen Li Fei Supervisors
Hu Liang Bin senior management

Zhejiang Hisun Pharmaceutical Co Headlines

No Headlines